Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Cash Flow Reinvestment Rate
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Reinvestment Rate of 1.09x as of June 2023, reinvesting $44.49 Million (capex $31.00K plus investments $-44.46 Million) from operating cash flow of $40.67 Million. See Contineum Therapeutics, Inc. Class A Com (CTNM) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com operating cash flow efficiency.
Annual Cash Flow Reinvestment Rate for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year capital reinvestment analysis for Contineum Therapeutics, Inc. Class A Common Stock. See CTNM financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 3.41x | $65.98 Million | $19.35 Million | $414.00K | — |